title: In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y.
authors.forename: Michal
authors.initials: M
authors.lastname: Mazurek
authors.affiliation: University of Birmingham Institute of Cardiovascular SciencesBirmingham, England, UK.
authors.forename: Gregory Y H
authors.initials: GY
authors.lastname: Lip
mesh_terms: D003924:Diabetes Mellitus, Type 2; D006442:Glycated Hemoglobin; D006801:Humans; D007004:Hypoglycemic Agents; D000069450:Liraglutide; D012306:Risk; D016896:Treatment Outcome
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000069450:Liraglutide